| Management target | Revenue 25.0% FY27-29 |
|---|
| Revenue growth | Consolidated -19.2% YoY; Innoxel +165%; VHPL +52%. |
|---|---|
| Margins | Gross margins up 1,000 bps; EBITDA margin currently 9.1%. |
| Order book | ₹171 Cr (Tenders ₹119 Cr, Exports ₹33 Cr, Intl ₹20 Cr). |
| Demand visibility | Strong order book of ₹171 Cr for standalone BPL. |
| Management confidence | High on subsidiary scaling and margin normalization. |
Growth
Subsidiaries Innoxel (+165% YoY) and Varenyam Healthcare (+52% YoY) drove growth, now contributing 46% of gross revenue.
Outlook
Management guides Innoxel revenue of ₹70-90 Cr for FY27 and EBITDA break-even; targeting US/EU CDMO scaling.
Risks
Consolidated EBITDA decline driven by increased operating expenses and Innoxel's ₹(10.4) Cr loss pre-breakeven.
Investor Presentation filed with BSE, BSE: 541096. Summary written with AI assistance from the document.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,895.10
- Market cap
- ₹1,306 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- -84.8×Sector 50.4×
- Promoter holding
- 67.20%+0.03% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Board Meeting Date
Bharat Parenterals intimated that its Board will meet on 29 September 2026 to consider a preferential equity issue. The agenda item is proposed, not yet approved, with no amount disclosed.
Bharat Parenterals Management Change
Bharat Parenterals Limited has re-appointed Mr. Hemang Jayendrabhai Shah as Executive Director for a 5-year term effective July 2, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals Limited held its 33rd Annual General Meeting on September 19, 2026. The proceedings covered the adoption of financial statements and various resolutions.
Bharat Parenterals Q1 FY27 Results: Net Loss of ₹3.6 Cr, Loss Widens
Bharat Parenterals Ltd reported revenue from operations of ₹93.7 Cr (-19.2% YoY) and a net loss of ₹3.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹3.6 Cr
Bharat Parenterals Earnings Call: Key Takeaways
Bharat Parenterals reported flat FY26 consolidated revenue of ₹345.4cr but a 6x EBITDA surge to ₹15.8cr. Transition year focused on regulatory clearances and scaling subsidiaries like Innoxel and Varenyam.
Bharat Parenterals Earnings Call: Key Takeaways
Bharat Parenterals calls FY26 a 'bridge year' of transition, clearing regulatory hurdles and scaling subsidiaries despite flat consolidated revenue of ₹345.4 cr. Growth in high-margin subsidiaries Inoxxel and Verineum offset a 23% decline in standalone exports.